174561-02-5

Basic information

• Product Name: 1-[1-(4-fluorobenzyl)piperidin-4-yl]methanamine(SALTDATA: FREE)
• Synonyms: 1-[1-(4-fluorobenzyl)piperidin-4-yl]methanamine(SALTDATA: FREE);(1-(4-Fluorobenzyl)piperidin-4-yl)MethanaMine
• CAS NO: 174561-02-5
• Molecular Formula: C₁₃H₁₉FN₂
• Molecular Weight: 222.3017632
• Mol File: 174561-02-5.mol

Chemical Properties

• Boiling Point: 308.1±17.0 °C(Predicted)
• Appearance: /
• Density: 1.085±0.06 g/cm3(Predicted)
• PKA: 10.13±0.29(Predicted)
• CAS DataBase Reference: 1-[1-(4-fluorobenzyl)piperidin-4-yl]methanamine(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[1-(4-fluorobenzyl)piperidin-4-yl]methanamine(SALTDATA: FREE)(174561-02-5)
• EPA Substance Registry System: 1-[1-(4-fluorobenzyl)piperidin-4-yl]methanamine(SALTDATA: FREE)(174561-02-5)

Safety Data

• Hazardous Substances Data: 174561-02-5(Hazardous Substances Data)

Usage

Molecular Weight

247.34 g/mol

Structure

Piperidine derivative containing a fluorobenzyl group

Industry

Pharmaceutical

Potential Applications

Drug candidate for various medical conditions

Studied Properties

Anti-inflammatory and analgesic

Significance

Promising candidate for research and development in medicinal chemistry

Functional Groups

Piperidine ring
Fluorobenzyl group
Methylamine group

Physical State

Likely a solid at room temperature (based on molecular weight and structure)

Stability

Stable under normal conditions, but sensitive to heat, light, and moisture (common for pharmaceutical compounds)

Reactivity

May react with strong acids, strong bases, or oxidizing agents (typical for compounds with amine and fluorine-containing groups)

Synthesis

Multi-step synthesis involving the formation of the piperidine ring, introduction of the fluorobenzyl group, and subsequent functionalization to introduce the methylamine group

Purity

Typically synthesized and used in a pure form for pharmaceutical applications

Safety

Handle with care, using appropriate personal protective equipment (PPE) such as gloves, goggles, and a lab coat, as it may have potential health risks due to its pharmaceutical nature

Disposal

Dispose of in accordance with local regulations and guidelines for pharmaceutical waste, ensuring proper containment and neutralization of the compound before disposal

Environmental Impact

Potentially harmful to the environment if released in large quantities, so proper handling and disposal are crucial to minimize environmental impact

Upstream product

• 39546-32-2 4-carboxamidopiperidine 
• 459-46-1 4-Fluorobenzyl bromide 
• 380424-12-4 1-(4-fluoro-benzyl)-piperidine-4-carboxylic acid amide 
• 174561-04-7 1-[(4-fluorophenyl)methyl]-4-(hydroxymethyl)piperidine 

Relevant articles and documents

Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer’s disease

Cholinesterase inhibitor plays an important role in the treatment of patients with Alzheimer’s disease (AD). Herein, we report the medicinal chemistry efforts leading to a new series of 1,3-dimethylbenzimidazolinone derivatives. Among the synthesised compounds, 15b and 15j showed submicromolar IC50 values (15b, eeAChE IC50 = 0.39 ± 0.11 μM; 15j, eqBChE IC50 = 0.16 ± 0.04 μM) towards acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Kinetic and molecular modelling studies revealed that 15b and 15j act in a competitive manner. 15b and 15j showed neuroprotective effect against H2O2-induced oxidative damage on PC12 cells. This effect was further supported by their antioxidant activity determined in a DPPH assay in vitro. Morris water maze test confirmed the memory amelioration effect of the two compounds in a scopolamine-induced mouse model. Moreover, the hepatotoxicity of 15b and 15j was lower than tacrine. In summary, these data suggest 15b and 15j are promising multifunctional agents against AD.

Pyrimidine derivatives

Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula STR1 wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1 -C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1 -C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1 -C6 alkyl group, a C3 -C6 cycloalkyl group, an aryl group or the like; R4 is --SR7 or --NR8 R9 wherein R7 is a C1 -C6 alkyl group; R8 is a C1 -C6 alkyl group or the like; R9 is a hydrogen atom, a C1 -C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) STR2 wherein R10 represents a C1 -C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.